Global Home Global Home  
 
 

News

Date Title and Summary Additional Formats
Toggle Summary Sonoma Pharmaceuticals Announces Pricing of Public Offering of Units
PETALUMA, Calif. , Nov. 17, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the pricing of a “best efforts” public offering of units consisting of one share of common stock, together with one half of one warrant to purchase one share of common stock at an
View HTML
Toggle Summary Sonoma Pharmaceuticals’ Settlement of Litigation Against Collidion
Sonoma Pharmaceuticals’ Settlement of Litigation Against Collidion PETALUMA, Calif. —(November 9, 2018)— Sonoma® Pharmaceuticals, Inc. (Nasdaq: SNOA) Sonoma Pharmaceuticals, Inc. (“Sonoma”) and Collidion Inc. (“Collidion”) have today announced agreement to settle Sonoma’s claims of trade secret
View HTML
Toggle Summary Sonoma Pharmaceuticals Reports Record Revenue in Second Quarter FY 2019
•  Total Revenue of $4.9 Million , up 13 % over June 2018 Quarter •  Total Revenue up 14% over September 2017 Quarter Conference Call Begins at 4:30 pm EST Today PETALUMA, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced financial results for
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Second Quarter FY 2019 Financial Results and Conference Call
PETALUMA, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced that financial results for its fiscal year 2019 second quarter, ended September 30, 2018 , will be released after the U.S. markets close on November 8, 2018 .
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Newly Published Results from Study of Hypochlorous Acid in Management of Hypertrophic and Keloid Scars
PETALUMA, Calif. , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced newly published results from a study into the use of the company’s proprietary Performance Stabilized HOCl TM (hypochlorous acid) for the management of scars.
View HTML
Toggle Summary Sonoma Pharmaceuticals Launches New Ceramax™ Skin Barrier Lotion with Skin-Enriching Lipogrid Technology™
PETALUMA, Calif. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced the launch of a new
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Licensing of Antimicrobial Hypochlorous Acid Solution for Management of Blepharitis in the Spanish/Portuguese Markets to Brill Pharma, S.L.
PETALUMA, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced it has licensed its
View HTML
Toggle Summary Sonoma Pharmaceuticals Appoints Phillipe Weigerstorfer to Board of Directors
PETALUMA, Calif. , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced the appointment of Philippe Weigerstorfer to the company’s board of directors.  Weigerstorfer brings extensive pharmaceutical and dermatology experience to Sonoma’s board with a track
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Results from Study of Sonoma’s Performance-Stabilized HOCl™ (Hypochlorous Acid) in Management of Acne Vulgaris
Lead Researcher Mark Steven Nestor, M.D., Ph.D. Presented the Results of the Study at the Practical Symposium Dermatology Conference August 9-12, 2018 PETALUMA, Calif. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced that results from a study into the
View HTML
Toggle Summary Sonoma Pharmaceuticals Reports First Quarter FY 2019 Financial Results
Total Revenue up 20 % over March 2018 Quarter Total Revenue up 14% over June 2017 Quarter Conference Call Begins at 4:30pm EDT Today PETALUMA, Calif. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced financial results for the first quarter FY 2019
View HTML